MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2024 International Congress

    Comparison in Therapeutic Outcome of Ultrasound-Guided Botulinum Injections for Limb Spasticity Versus Dystonia

    G. Yahalom, M. Cohen, I. Israel, R. Eichel, Y. Schechter (Jerusalem, Israel)

    Objective: To compare the therapeutic efficacy of BT injections for spasticity and dystonia in the limbs. Background: Botulinum toxin (BT) shows promise in alleviating limb…
  • 2024 International Congress

    Real-World Retrospective Safety Analysis in Patients Treated With OnabotulinumtoxinA for Multiple Therapeutic Indications Over Repeat Treatment Periods

    G. Forde, A. Patel, K. Martinez, A. Mayadev, B. Brucker, T. Brown, Z. Ayyoub, R. Singh, M. Nelson, A. Ukah, I. Yushmanova, S. Battucci, K. Becker Ifantides, C. Rhyne (New Hyde Park, USA)

    Objective: To evaluate the real-world safety of onabotulinumtoxinA (onabotA) use over repeat treatment periods (TPs) in patients (pts) with concomitant multiple therapeutic indications. Background: In…
  • 2024 International Congress

    Demographics of Botulinum toxin therapy population representative to demographics in Essex County, USA

    B. Puccio, Y. Xu, J. Acquaviva, E. Feinstein (Newark, USA)

    Objective: To describe and compare the demographics of patients receiving botulinum toxin therapy in a single movement disorder clinic to the broader surrounding community. Background:…
  • 2024 International Congress

    Tardive Dystonia Following Risperidone Treatment : A Case Report and Therapeutic Approach

    M. Hildaria, D. Tunjungsari, A. Tiksnadi (Central Jakarta, Indonesia)

    Objective: To report a case of tardive dystonia induced by risperidone and discuss the therapeutic approach, including the use of botulinum toxin. Background: Risperidone, a…
  • 2024 International Congress

    Disparities in Botulinum Toxin Utilization for Cervical Dystonia in a United States Medicare Population

    M. Verduzco-Gutierrez, A. Keener, I. Howard, D. Torres-Russotto, J. Sparrow, R. Kazerooni (San Antonio, USA)

    Objective: To examine the disparities in utilization of botulinum toxin (BoNT) injections for patients with cervical dystonia (CD) within the United States Medicare population. Background:…
  • 2024 International Congress

    Perceptions of Diseases in Patients with Cervical Dystonia

    D. Talkington, D. Sblendorio, K. Pyle, M. Coleman, M. Patel, M. Moreno-Escobar, A. Murray, A. Memon, J. Frey (Morgantown, USA)

    Objective: To explore how perception of disease can impact stigma, mood, quality of life, and severity of symptoms in patients with cervical dystonia (CD). Background:…
  • 2024 International Congress

    Botulinum Toxin and Deep Brain Stimulation in Dystonia

    J. Souza, A. Falcone, R. Barbosa, M. Soares, R. Munhoz, M. Farah, T. Capato, S. Casagrande, M. Cordellini, G. Micheli, J. Limongi, E. Barbosa, C. Listik, R. Cury (Sao Paulo, Brazil)

    Objective: The primary outcome was the relationship between BoNT dosage and DBS surgery in each muscle. A secondary analysis of BoNT dosages through different muscle…
  • 2024 International Congress

    Do Lower Doses of Botulinum Neurotoxin Type-A Offer a Longer Duration of Effect and Superior Efficacy in Patients with Cervical Dystonia?

    A. Kundrick, H. Fernandez (Cleveland, USA)

    Objective: To determine if there is a difference in efficacy and duration of effect between high-dose and low-dose botulinumtoxin neurotoxin type-A for cervical dystonia. Background:…
  • 2024 International Congress

    Efficacy Remaining at Time of Requested Retreatment Following Botulinum Toxin Treatment for Cervical Dystonia: Potential for a New Treatment Paradigm with DaxibotulinumtoxinA

    A. Ellenbogen, R. Hauser, A. Patel, P. Mcallister, D. Vitarella, T. Gross, R. Kazerooni, C. Gallagher, D. Hollander (Farmington Hills, USA)

    Objective: To assess the residual therapeutic efficacy of prior botulinum toxin (BoNT) injection at the patient-desired retreatment interval in cervical dystonia (CD). Background: BoNT injections…
  • 2024 International Congress

    Efficacy and Safety of DaxibotulinumtoxinA-lanm for Injection in Adults with Cervical Dystonia: Pooled Global Analysis of ASPEN-1 and ASPEN-1-CN

    D. Truong, H. Xingyue, A. Ellenbogen, J. Lingjing, K. Dashtipour, A. Patel, T. Gross, R. Kazerooni, C. Gallagher, F. Xiaojin, S. Yunan, G. Lei, W. Xinhua, D. Hollander (Riverside, USA)

    Objective: To evaluate the pooled efficacy and safety of 2 doses of DaxibotulinumtoxinA-lanm for injection (DAXI) for the treatment of cervical dystonia (CD) in 2…
  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Welcome to the MDS Abstracts Site
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Life expectancy with and without Parkinson’s disease in the general population
    • The hardest symptoms that bother patients with Parkinson's disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley